<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627428</url>
  </required_header>
  <id_info>
    <org_study_id>RPESC-RPE-01</org_study_id>
    <secondary_id>U01EY030581</secondary_id>
    <secondary_id>UG3EY031810</secondary_id>
    <nct_id>NCT04627428</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of RPESC-derived RPE Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)</brief_title>
  <official_title>A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPESC-derived RPE Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luxa Biotechnology, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regenerative Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luxa Biotechnology, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W&#xD;
      as therapy for dry AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RPESC-RPE-4W is Allogeneic RPE stem cell (RPESC)-derived RPE cells (RPESC-RPE) isolated from&#xD;
      the RPE layer of human cadaveric eyes are transplanted under the macular.&#xD;
&#xD;
      This first-in-human Phase 1/2a open-label dose-escalation interventional study plans to&#xD;
      enroll a total of 18 subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of RPESC-RPE-4W transplantation</measure>
    <time_frame>24 months</time_frame>
    <description>The transplantation of RPESC-RPE-4W cells will be considered safe and tolerated in the absence of:&#xD;
Decrease in visual acuity (VA) of more than 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (or to worse than counting fingers at three feet) from baseline&#xD;
Any Grade 2 (CTCAE version 5) or greater Adverse Events (AE) related to the cell product and investigational interventions.&#xD;
Any evidence that the cell are contaminated with an infectious agent or serious immune response to the cell product&#xD;
Any evidence that the cells show tumorigenic potential</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the mean of Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>24 months</time_frame>
    <description>Change in visual acuity will be measured by ETDRS chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of ≥10 decibels of ten-degree average visual sensitivity microperimetry</measure>
    <time_frame>24 months</time_frame>
    <description>Loss of ≥10 decibels of ten-degree average visual sensitivity will by measured by microperimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GA lesion area</measure>
    <time_frame>24 months</time_frame>
    <description>Change in GA lesion area will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of structural changes</measure>
    <time_frame>24 months</time_frame>
    <description>Structural evidence will be measured by OCT imaging, autofluorescence, fluorescein angiography, and fundus photography</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>50,000 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150,000 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250,000 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RPESC-RPE-4W</intervention_name>
    <description>RPESC-RPE-4W</description>
    <arm_group_label>150,000 cells</arm_group_label>
    <arm_group_label>250,000 cells</arm_group_label>
    <arm_group_label>50,000 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of dry AMD.&#xD;
&#xD;
          2. Ability to understand and give informed consent.&#xD;
&#xD;
          3. Adult male or female &gt;55 years of age.&#xD;
&#xD;
          4. Medically suitable to undergo vitrectomy and subretinal injection (&gt;60% on Karnofsky&#xD;
             scale).&#xD;
&#xD;
          5. Postmenopausal if female (expected to be common for the age limitation), or the female&#xD;
             partner of a male subject unable to father children.&#xD;
&#xD;
          6. If male, willing to use barrier and spermicidal contraception during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or hypersensitivity to dilation drops or fluorescein.&#xD;
&#xD;
          2. Active major medical conditions limiting ability to participate in the study.&#xD;
&#xD;
          3. Active malignancy or treatment with chemotherapy.&#xD;
&#xD;
          4. Systemic immunosuppressant therapy within past six months.&#xD;
&#xD;
          5. History of toxoplasmosis, retinal histoplasmosis or tuberculosis.&#xD;
&#xD;
          6. Receipt of investigational product (IP) in a clinical trial within prior six months.&#xD;
&#xD;
          7. Any other medical condition, which, in the Investigator's judgment, will interfere&#xD;
             with the subject's ability to comply with the protocol, compromises subject safety, or&#xD;
             interferes with the interpretation of the study results.&#xD;
&#xD;
          8. Pregnant or nursing females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh C Rao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Kellogg Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey H Stern, M.D., Ph.D.</last_name>
    <phone>05184371111</phone>
    <email>jeffreystern@luxabiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rajesh C Rao, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

